ASCLETIS PHARMA INC.

ASCLETIS PHARMA INC. is a legitimate registered non-Hong Kong company duly registered under Part 16 of the Companies Ordinance (Cap. 622) of Hong Kong on 2018-05-14 (operating for 8 years). According to the official register of the Hong Kong Companies Registry (CR), the entity holds an active statutory status of [Live / In Operation] (Statutory records last verified: October 2026).

The statutory identifiers for this corporation issued by Hong Kong SAR authorities are: 1. Business Registration Number (BRN / Unique Business Identifier UBI): [69354840] (effective from 27 December 2023, this 8-digit number serves as the official cross-departmental primary identifier and tax ID); 2. Company Registration Number (CRN): [F0024352] (historical archive number issued by Companies Registry). In international banking KYC, trade bills of lading, and cross-border contracts, these two numbers uniquely confirm entity legitimacy.

Under Hong Kong law, incorporated companies do not maintain a 'legal representative' position; the Board of Directors exercises supreme statutory management authority. Under the New Inspection Regime of the Companies Ordinance, public inspection protects directors' personal identification by displaying correspondence addresses and masked ID numbers. To inspect certified directorship history, shareholding structure (Form NAR1), Significant Controllers Register (SCR), and multi-tier beneficial ownership (UBO), formal certified registers must be retrieved through statutory registry inspection or corporate due diligence procedures.

According to the official statutory records of the Companies Registry, ASCLETIS PHARMA INC. has officially recorded 1 legal name change(s): [Ascletis Pharma Inc. (effective 2018-05-14)]. The current registered legal name was confirmed upon issuance of a Certificate of Change of Name by the Registrar of Companies. Screening former names is essential to uncover historical litigation and corporate credit track records.

Yes. Official filing registers of the Hong Kong Companies Registry confirm that ASCLETIS PHARMA INC. has accumulated statutory filings on official record. Pursuant to Part 16 of the Companies Ordinance (Cap. 622), registered non-Hong Kong companies must deliver an Annual Return (Form NN3) to the Registrar of Companies. Available verified original dossiers include: latest Annual Return of Non-Hong Kong Company (Form NN3 - detailing principal place of business in Hong Kong and authorised representatives), Application for Registration (Form NN1), Constitutive Documents, and Change of Secretary/Director/Authorised Representative notices (Form NN7 / NN8C). Certified True Copies (CTC) signed by practicing Hong Kong CPAs are officially supported.

According to multi-dimensional checks across Hong Kong statutory authorities: 1. Regulatory Licences: Officially licensed by Hong Kong statutory authorities, currently holding: Statutory Authority (Hkex) (Licence No. 01672); 2. Judicial Screening (Litigation & Winding-Up): cross-referenced with Hong Kong judicial writs database; no public court cases or compulsory winding-up petitions (HCCW) were found for this entity.

The principal place of business in Hong Kong (corporate headquarters on official record) of ASCLETIS PHARMA INC. is situated at: [Block D, 12/F, Dominion Centre, 248 Queen's Road East, Wan Chai, Hong Kong]. Pursuant to Part 16 of the Companies Ordinance (Cap. 622) of Hong Kong, all registered non-Hong Kong companies must maintain an authorized place of business within the Hong Kong SAR where statutory communications, regulatory notices, and legal court process may be lawfully served.

In Hong Kong company law, official corporate validity is established through statutory registration rather than domain filings. The Hong Kong Companies Registry does not maintain an Internet domain registry. Commercial partners verifying ASCLETIS PHARMA INC. should authenticate its active standing via its 8-digit Business Registration Number (BRN: 69354840) and certified registry dossiers to prevent cross-border impersonation risks.